

DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

Relevant Financial Relationships

The following individuals involved in the planning, development, review, presentation, authoring and/or editing of the symposium content have disclosed relevant financial relationships with ineligible companies*, and the CME Department has mitigated these potential conflicts of interest. **Indicates that this individual's presentation(s) **will include** discussion of off-label or unapproved usage.

- **Manmeet Ahluwalia, M.D.**, faculty and planner of this educational activity, is a researcher for Seagen. He is a consultant for Bayer, Insightec, Xoft, Cellularity, Apollomics, Janssen, Voyager Therapeutics, Novocure, GSK, Nuvation Bio, SDP Oncology, Prelude, Tocagen, Viewray, Caris Lifesciences, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem Therapeutics, GT Medical Technologies, Modifi Biosciences, bugworks, Allovir and Equillium Bio. He is an advisor for GRN and VBI Vaccines. He holds stock options in Mimivax, Cytodyn, MedInnovate Advisors and Trisalus Lifesciences.
- **John Diaz, M.D.**, faculty for this educational activity, is a researcher for Merck and AstraZeneca.
- **Don Dizon, M.D.****, faculty for this educational activity is an advisor for Pfizer, AstraZeneca, GSK and Clovis.
- **Petros Grivas, M.D.****, faculty for this educational activity has received research funding from Acrivon Therapeutics; ALX Oncology, Bavarian Nordic; Bristol-Myers Squibb; Clovis Oncology; Debiopharm; Merck KGaA; Gilead; Pfizer; MSD; QED Therapeutics; GlaxoSmithKline; G1 Therapeutics; Mirati Therapeutics and is a consultant for Aadi Bioscience; AstraZeneca; Asieris Pharmaceuticals, Astellas Pharma, Bristol-Myers Squibb; Boston Gene, CG Oncology, Dyania Health; Lucence Health; Fresenius Kabi, G1 Therapeutics; Gilead; Guardant Health; ImmunityBio; Janssen; Merck KGaA; MSD; Pfizer; PureTech; Roche, SeaGen, Strata Oncology, Silverback Therapeutics.
- **Shilpa Gupta, M.D.**, faculty for this educational activity is a researcher with Moderna, BMS, Merck, Roche, Exelixis, Novartis, Acrivon, QED, Seattle Genetics, Gilead, Guardant, Foundation Medicine, Bayer, Sanofi and Astellas. She is on the speakers bureau for Gilead, Seattle Genetics and Astellas. She holds stock options with Moderna, Bon Tech and Nektar Therapeutics.
- **Ian Krop, M.D.**, faculty for this educational activity has received research funding from Pfizer and Genentech/Roche. He is a consultant for AstraZeneca, Daiichi Sankyo and Genentech/Roche. He is on the speaker's bureau for Daiichi Sankyo. He is a DSMC member for Novartis and Merck.
- **Reshma Mahtani, D.O.****, faculty for this educational activity is a consultant for Agendia, Amgen, Astra Zeneca, Daiici, Eisai, Genentech, Gilead, Hologic, Novartis, Pfizer, Puma, Sanofi, Stemline, and Sermonix.
- **Ingo Mellinshoff, M.D.**, faculty for this educational activity, is a researcher for Erasca, Global Coalition for Adaptive Research and Servier Pharmaceuticals. He is a consultant for Voyager Therapeutics, Black Diamond Therapeutics and Prelude Therapeutics. He is an advisor for F. Hoffman-La Roche and Tango. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

- **Joyce O'Shaughnessy, M.D.**, faculty for this educational activity is a consultant for Agendia, Aptitude Health, AstraZeneca, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Lilly, Merck, Novartis, Ontada and Pfizer.
- **Rachna Shroff, M.D.**, faculty for this education activity has received research support from Bayer, BMS, Exelixis Pharm. IMV Inc., LOXO, Merck, NUCUNA, Oieris, QED Therapeutics, Rafael, Seagen and Tacho. Is a consultant for SYROS, Hookipa Pharm., AbbVie and Ability Pharm. Is an advisor for AstraZeneca, Boehringer Ingelheim, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Taiho, Zymeworks Bio, Asetellas and Duo.
- **Brian Slomovitz, M.D.**, faculty for this educational activity is a consultant for AbbVie, AstraZeneca, Novocure, Lilly, Seagen, Genmab, GOG Foundation, GSK and is on the speaker's bureau for Seagen.
- **Neeta Somaiah, M.D.**, faculty for this educational activity is an advisor for Deciphera, Boehringer Ingelheim and AdaptImmune and is a researcher for Deciphera, Boehringer Ingelheim, Ascentage, IDRX, AstraZeneca, and Cogent.
- **Vamsi Velcheti, M.D.**, faculty for this educational activity is a consultant for BMS, Merck, AstraZeneca, Amgen, Taiho, Takeda, Daiichi Sankyo, GSK Oncology, Picture Health, Novocure and Regeneron.
- **Patrick Wen, M.D.**, faculty for this educational activity has received research and grant support from Kazia, MediciNova, Merck, Novartis, Quadriga, Servier, and VBI Vaccines. Is a consultant for Anheart, AstraZeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, GSK, Kinatara, Merck, Mundipharma and Novartis. Is an advisor for Novocure, Prelude Therapeutics, Sagimet, Sapience, Servier, Symbio, Tango, Telix and VBI Vaccines. Has other financial relationships with AstraZeneca, Black Diamond, BMS, Chimerix, Eli Lilly, Erasca and Global Coalition Adaptive Research.
- **Robin Zon, M.D.**, faculty for this educational activity has stock and other ownership interests in AC3 Healthcare Technology, Cytosorbents, Moderna, Oncolytics Biotech, TG Therapeutics, Select Sector SPDR Health Care, AstraZeneca, Crispr, McKesson, Athenex, Johnson & Johnson/Janssen, ARK Genomic Revolution, iShafes Biotechnology ETF, Vanguard World Healthcare ETF, Berkshire Hathaway and Seagen. She is a consultant/advisor for New Century Health, Abbvie, Sanofi, Canopy, and LabCorp. She also has a relevant financial relationship with Cincinnati Cancer Advisors.

Nothing to Disclose

- **Rohan Garje, M.D.**, faculty for this educational activity, has no relevant financial relationships with ineligible companies to disclose.
- **Everett Vokes, M.D.**, faculty for this educational activity, has no relevant financial relationships with ineligible companies to disclose.
- **Stacey Berrios, P.A.-C.**, content reviewer for this activity, has no relevant financial relationships with ineligible companies to disclose.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies to disclose.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*